Pfizer Inc., Novartis AG, Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) are Dominating the Global Menopausal Disorder Treatment Market in 2019

Global Menopausal Disorder Treatment Market is expected to grow with the CAGR of 7.4% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-menopausal-disorder-treatment-market

Global menopausal disorder treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global menopausal disorder treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In September 2019, Novartis AG achieved positive result from MONALEESA-3 trial which showed that Kisqali is a safe and effective drug which can be used for treatment of post-menopausal disorder in patients who experiences breast cancer as one of the post-menopausal disorder. This product reported to increase life of breast cancer patients a symptom associated with menopause. This result helped the company to expand its roots in menopausal disorder treatment market.

Pfizer, Inc. is the dominating player in global menopausal disorder treatment market. The other key players existing in the market are Eli Lilly and Company, Allergan (A Subsidiary of AbbVie, Inc.), TherapeuticsMD, Inc., GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Ipsen Pharma, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Mylan N.V., Abbott, Besins Healthcare, Mithra Pharmaceuticals, Aché Laboratórios Farmacêuticos S.A, SEBELA PHARMACEUTICALS, Fervent Pharmaceuticals Inc., KaNDy Therapeutics, Sojournix Inc., Duchesnay USA, Novartis AG, Novo Nordisk A/S among others.

 Menopausal Disorder Treatment MarketPfizer Inc.

Pfizer Inc. is headquartered in New York, U.S. The company is focused on providing standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. The company has multiple business segments including Biopharma, Upjohn and Consumer Healthcare in these Biopharma, Upjohn are the market focused segment. The company is offering large number of products such as ACCUPRIL, ALTACE, AZITHROMYCIN,DEPO-PROVERA, DEPO-SUBQ PROVERA 104, DEPO-ESTRADIOL, ESTRING, ENBREL (ETANERCEPT) IBRANCE, INFLECTRA, INSPRA, METHOTREXATE,LO/OVRAL, MENEST, NORMINEST FE, NORQUEST FE, OGEN, PREMARIN, PREMPRO, PREMPHASE, PROVERA, TRIPHASIL-21, TRIPHASIL-28, ZOLOFT among others in which DEPO-PROVERA, DEPO-SUBQ PROVERA 104, DEPO-ESTRADIOL, ESTRING, LO/OVRAL, MENEST, NORMINEST FE, NORQUEST FE, OGEN, PREMARIN, PREMPRO,PREMPHASE, PROVERA, TRIPHASIL-21, TRIPHASIL-28, ZOLOFT are the market focused products.

For instance,

  • In December 2018, Pfizer Inc. and GlaxoSmithKline PLC signed an agreement to form a new consumer healthcare joint venture. As the company is focused on manufacturing of prescription medicines involving hormonal therapies used for menopausal disorder treatment this initiative helped it to strengthen its pharmaceutical product portfolio.

The company has wide presence across Europe, Middle East & Africa, Americas, Asia-Pacific. The company also has various subsidiary companies such as Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic), Pfizer Egypt S.A.E. (Egypt) among others.

Novartis AG

Novartis AG is headquartered in Basel, Switzerland founded in 1996. The company is engaged in investing in the most promising frontiers of science, the most exciting innovation in the business of medicines and the most significant healthcare needs. The company operates its business through multiple business segments that are Innovative Medicines, Sandoz in which Innovative Medicines is the market focussed business segment. The company has wide number of products including Aimovig 70 mg solution for injection, Estradot 100 micrograms/24 hours, transdermal patch, Estradot 25 micrograms/24 hours, transdermal patches, Estradot 37.5 micrograms/24 hours, transdermal patches, Estradot 25, 37.5, 50, 75 and 100 micrograms/24 hours, transdermal patches, Estradot 50 micrograms/24 hours, transdermal patch, Estradot 75 micrograms/24 hours, transdermal patch, Afinitor Tablets, Votubia 1mg, 2mg, 3mg and 5mg Dispersible Tablets, Zometa 4mg/100ml Solution for Infusion, Aclasta 5 mg solution for infusion among many more in which Estradot 100 micrograms/24 hours, transdermal patch, Estradot 25 micrograms/24 hours, transdermal patches, Estradot 37.5 micrograms/24 hours, transdermal patches, Estradot 25, 37.5, 50, 75 and 100 micrograms/24 hours, transdermal patches, Estradot 50 micrograms/24 hours, transdermal patch, Afinitor Tablets, Estradot 75 micrograms/24 hours, transdermal patch are the market focused products.

For instance,

  • In May 2020, Novartis AG received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Piqray to be used in combination with fulvestrant for treatment of metastatic breast cancer, a disease associated with menopause. This positive opinion helped the company to advance its menopausal disorder treatment market in European region.

The company has presence across Americas, Europe, Asia-Pacific, Middle East & Africa. The company has various subsidiaries such as Sandoz Pty Ltd, Macquarie Park, (New South Wales, Australia), Sandoz GmbH, Kundl (Austria), Sandoz NV, Vilvoorde (Belgium), Sandoz do Brasil Indústria Farmacêutica Ltda., Cambé, PR (Brazil), Sandoz s.r.o., Prague (Czech Republic ) among others.

Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)

Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) is headquartered in New Jersey, U.S. The company is focused on generics and biopharmaceuticals market with an aim to improve the lives of patients. The company is has wide product portfolio which involves Generic Medicines, Specialty Medicines, Biopharmaceuticals in which Generic Medicines is the market focused product.

For instance,

  • In July 2017, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) launched generic Vagifem in the U.S. market. The product lsunched by the company is estradiol vaginal insert which can be used for treatment for atrophic vaginitis associated with menopause. This product launch enhanced the company’s generic product portfolio and allowed it to penetrate its root in menopausal disorder treatment market.

The company is present in North America.